MDMB-4en-PINACA (also incorrectly known as 5-CL-ADB-A) is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. In 2021, MDMB-4en-PINACA was the most common synthetic cannabinoid identified by the Drug Enforcement Administration in the United States. MDMB-4en-PINACA differs from 5F-MDMB-PINACA due to replacement of 5-fluoropentyl with a pent-4-ene moiety (4-en).
It acts as a potent agonist of the CB1 receptor with an EC50 value of 2.47 nM.
Legal status
Sweden's public health agency suggested classifying MDMB-4en-PINACA as a hazardous substance, on December 18, 2019.
In the United States, the DEA has filed a notice for its intent to temporarily place MDMB-4en-PINACA into Schedule I status starting on or after May 4th, 2023 for up to 2 years, during which it's possible the DEA could file for permanent scheduling within those 2 years. If it's filed on May 4, 2023, and the DEA does not file to permanent placement the temporary Schedule I order will expire on May 4, 2025.
North Dakota has placed MDMB-4en-PINACA into Schedule I on 04/27/2023.